Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension
- PMID: 10458725
- DOI: 10.1161/01.cir.100.8.869
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension
Abstract
Background: Coadministration of phentermine and fenfluramine (phen/fen) effectively treats obesity and possibly addictive disorders. The association of fenfluramine and certain other anorexic agents with serious side effects, such as cardiac valvulopathy and primary pulmonary hypertension (PPH), limits the clinical utility of these drugs. Development of new medications that produce neurochemical effects like phen/fen without causing unwanted side effects would be a significant therapeutic breakthrough.
Methods and results: We tested the hypothesis that fenfluramine (and other anorexic agents) might increase the risk of PPH through interactions with serotonin (5-HT) transporters. Because 5-HT transporter proteins in the lung and brain are identical, we examined, in rat brain, the effects of selected drugs on 5-HT efflux in vivo and monoamine transporters in vitro as a generalized index of transporter function. Our data show that drugs known or suspected to increase the risk of PPH (eg, aminorex, fenfluramine, and chlorphentermine) are 5-HT transporter substrates, whereas drugs that have not been shown to increase the risk of PPH are less potent in this regard.
Conclusions: We speculate that medications that are 5-HT transporter substrates get translocated into pulmonary cells where, depending on the degree of drug retention, their intrinsic drug toxicity, and individual susceptibility, PPH could develop as a response to high levels of these drugs or metabolites. Emerging evidence suggests that it is possible to develop transporter substrates devoid of adverse side effects. Such medications could have therapeutic application in the management of obesity, drug dependence, depression, and other disorders.
Similar articles
-
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications.Synapse. 2000 May;36(2):102-13. doi: 10.1002/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#. Synapse. 2000. PMID: 10767057
-
Therapeutic and adverse actions of serotonin transporter substrates.Pharmacol Ther. 2002 Jul;95(1):73-88. doi: 10.1016/s0163-7258(02)00234-6. Pharmacol Ther. 2002. PMID: 12163129 Review.
-
Serotonin releasing agents. Neurochemical, therapeutic and adverse effects.Pharmacol Biochem Behav. 2002 Apr;71(4):825-36. doi: 10.1016/s0091-3057(01)00669-4. Pharmacol Biochem Behav. 2002. PMID: 11888573 Review.
-
1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain.Neuropsychopharmacology. 2001 May;24(5):492-501. doi: 10.1016/S0893-133X(00)00221-9. Neuropsychopharmacology. 2001. PMID: 11282249
-
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.Eur J Pharmacol. 2002 Jun 7;445(1-2):69-81. doi: 10.1016/s0014-2999(02)01751-x. Eur J Pharmacol. 2002. PMID: 12065196
Cited by
-
Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension.Cardiovasc Res. 2013 Jul 1;99(1):24-34. doi: 10.1093/cvr/cvt064. Epub 2013 Mar 20. Cardiovasc Res. 2013. PMID: 23519266 Free PMC article.
-
Investigation of Genes and Proteins Expression Associating Serotonin Signaling Pathway in Lung and Pulmonary Artery Tissues of Dogs with Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease: The Preliminary Study.Vet Sci. 2022 Sep 28;9(10):530. doi: 10.3390/vetsci9100530. Vet Sci. 2022. PMID: 36288144 Free PMC article.
-
Toward a broader view of mechanisms of drug cardiotoxicity.Cell Rep Med. 2021 Mar 16;2(3):100216. doi: 10.1016/j.xcrm.2021.100216. eCollection 2021 Mar 16. Cell Rep Med. 2021. PMID: 33763655 Free PMC article. Review.
-
(1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.Eur J Pharmacol. 2009 Aug 1;615(1-3):1-9. doi: 10.1016/j.ejphar.2009.04.035. Epub 2009 May 3. Eur J Pharmacol. 2009. PMID: 19397907 Free PMC article.
-
Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.Eur J Pharmacol. 2012 Jan 15;674(2-3):337-44. doi: 10.1016/j.ejphar.2011.10.033. Epub 2011 Nov 3. Eur J Pharmacol. 2012. PMID: 22079770 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
